This study is checking two treatments for a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). One treatment involves two drugs, BMS-986489, which combines atigotatug and nivolumab, and the other is a drug called durvalumab. These drugs are used after chemotherapy and radiotherapy to try and stop the cancer from coming back. Atigotatug is a special type of medicine that helps the immune system target cancer, and nivolumab helps the immune system fight cancer cells. Durvalumab also helps the immune system.

• Participants must be at least 18 years old and have completed chemotherapy and radiotherapy.
• Potential side effects and safety of the treatments will be closely monitored.
• The study will involve random assignment to one of the two treatment groups.

Participants will need to follow certain medical guidelines and maintain regular follow-ups throughout the study. Before joining, it's important to understand the possible risks and benefits and discuss with a healthcare provider.